Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate
Durability Test Remains
Executive Summary
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.
You may also be interested in...
GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development
Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.
GSK’s New Research Chief Begins Leadership With Expanded Genomics/AI Alliance
GSK’s new chief scientific officer Tony Wood is building on the precision medicine approach by partnering with Tempus to accelerate cancer drug trials and improve the firm’s R&D productivity.
Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.